ArticleFrontiers in oncology2026
Riboflavin (VB2) inhibits hepatocellular carcinogenesis by enhancing retinol metabolism and suppressing cell proliferation in Hras12V transgenic mice.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Riboflavin (VB2) is primarily utilized as an adjuvant in cancer therapy. This study aims to investigate the preventive and therapeutic effects of VB2 alone on hepatocellular carcinoma (HCC). Main methods: The preventive and therapeutic efficacy of VB2 against HCC was evaluated using a Hras12V transgenic mouse model of HCC. Initial mechanistic insights were obtained through transcriptome sequencing combined with bioinformatic analyses, and key findings were validated via molecular biology techniques. Key findings: VB2 administration significantly suppressed hepatic tumorigenesis, as evidenced by reductions in liver tumor burden and improved histology. Bioinformatic analysis revealed that VB2-mediated tumor suppression may involve the regulation of multiple metabolic pathways, including fatty acid and amino acid metabolism. Subsequent molecular validation indicated that VB2 enhanced hepatic retinol metabolism by upregulating key metabolic enzymes. It concurrently inhibited hepatocellular proliferation through p21-mediated G1/S phase arrest and suppressed DNA replication by downregulating the Mcm helicase complex. Additionally, VB2 exhibited inhibitory activity against the progression of established tumors, although this effect was not as significant as its suppression of hepatic tumorigenesis. Safety assessments in wild-type C57BL/6 mice revealed no significant treatment-related toxicity. Significance: To our knowledge, this study is the first to demonstrate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.